The immunology of Epstein-Barr virus infection

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 356, Issue 1408, 2001, Pages 475-488

  Moss, Denis J ^a   Burrows, Scott R ^b   Silins, Sharon L ^b   Misko, Ihor ^b   Khanna, Rajiv ^b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b NONE

Author keywords

Cytotoxic T lymphocyte; Epitope; Epstein Barr virus; Latent infection; Malignancy; Primary infection

Indexed keywords

ANIMALIA; DNA VIRUSES; HUMAN HERPESVIRUS 4;

EID: 0035967434     PISSN: 09628436     EISSN: None     Source Type: Journal    
DOI: 10.1098/rstb.2000.0784     Document Type: Review

References (115)

1. Ambinder, R. F., Robertson, K. D. & Tao, Q. 1999 DNA methylation and the Epstein-Barr virus. Semin. Cancer Biol. 9, 369-375.
2. Apolloni, A., Moss, D., Stumm, R., Burrows, S., Suhrbier, A., Misko, I., Schmidt, C. & Sculley, T. B. 1992 Sequence variation of cytotoxic T-cell epitopes in different isolates of Epstein-Barr virus. Eur. J. Immunol. 22, 183-189.
3. Argaet, V. P. (and 10 others) 1994 Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus. J. Exp. Med. 180, 2335-2340.
4. Babcock, G. J., Decker, L. L., Volk, M. & Thorley-Lawson, D. A. 1998 EBV persistence in memory B cells in vivo. Immunity 9, 395-404.
5. + T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 7, 791-802.
6. Blue, M. L., Daley, J. F., Levine, H. & Schlossman, S. F. 1985 Coexpression of T4 and T8 on peripheral blood T cells demonstrated by two-color fluorescence flow cytometry. J. Immunol. 134, 2281-2286.
7. Bogedain, C., Wolf, H., Modrow, S., Stuber, G. & Jilg, W. 1995 Specific cytotoxic T lymphocytes recognize the immediateearly transactivator Zta of Epstein-Barr virus. J. Virol. 69, 4872-4879.
8. Burrows, S. R., Misko, I. S., Sculley, T. B., Schmidt, C. & Moss, D. J. 1990a An Epstein-Barr virus specific T cell epitope in EBV nuclear antigen 3 (EBNA 3). J. Exp. Med. 171, 345-350.
9. Burrows, S. R., Misko, I. S., Sculley, T. B., Schmidt, C. & Moss, D. J. 1990b An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and B-type transformants. J. Virol. 64, 3974-3976.
10. Burrows, S. R., Gardner, J., Khanna, R., Steward, T., Moss, D. J., Rodda, S. & Suhrbier, A. 1994a Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3. J. Gen. Virol. 75, 2489-2493.
11. Burrows, S. R., Khanna, R., Burrows, J. M. & Moss, D. J. 1994b An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-verses-host disease. J. Exp. Med. 179, 1155-1161.
12. Burrows, S. R., Silins, S. L., Moss, D. J., Khanna, R., Misko, I. S. & Argaet, V. P. 1995 T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. J. Exp. Med. 182, 1703-1715.
13. Burrows, J. M., Burrows, S. R., Poulsen, L., Sculley, T. B., Moss, D. J. & Khanna, R. 1996 Unusually high frequency of Epstein-Barr virus genetic variants in Papua New Guinea that can escape cytotoxic T cell recognition: implications for HLA distribution and epitope loss. J. Virol. 70, 2490-2496.
14. Burrows, S. R., Silins, S. L., Cross, S. M., Peh, C. A., Rischmuller, M., Burrows, J, M., Elliott, S. L. & McCluskey, J. 1997a Human leukocyte antigen phenotype imposes complex constraints on the antigen-specific cytotoxic T lymphocyte repertoire. Eur. J. Immunol. 27, 178-182.
15. Burrows, S. R., Silins, S. L., Khanna, R., Burrows, J. M., Rischmuller, M., McCluskey, J. & Moss, D. J. 1997b Crossreactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity. Eur. J. Immunol. 27, 1726-1736.
16. + T cells in acute infectious mononucleosis. Nature Med. 2, 906-911.
17. + T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med. 187, 1395-1402.
18. + T cell memory in vivo. Eur. J. Immunol. 28, 4382-4390.
19. Carter, R. L. 1975 Infectious mononucleosis: model for self-limiting lymphoproliferation. Lancet i, 846-849.
20. Chen, Z. W., Kou, Z. C., Lekutis, C., Shen, L., Zhou, D., Halloran, M., Li, J., Sodroski, J., Lee-Parritz, D. & Letvin, N. L. 1995 T cell receptor V beta repertoire in an acute infection of rhesus monkeys with simian immunodeficiency viruses and a chimeric simian-human immunodeficiency virus. J. Exp. Med. 182, 21-31.
21. Couedel, C., Bodinier, M., Peyrat, M. A., Bonneville, M., Davodeau, F. & Lang, F. 1999 Selection and long-term persistence of reactive CTL clones during an EBV chronic response are determined by avidity, CD8 variable contribution compensating for differences in TCR affinities. J. Immunol. 162, 6351-6358.
22. Dardari, R., Khyatti, M., Benider, A., Jouhadi, H., Kahlain, A., Cochet, C., Mansouri, A., El Gueddari, B., Benslimane, A. & Joab, I. 2000 Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma. Int. J. Cancer. 86, 71-75.
23. De Campos-Lima, P. O., Gavioli, R., Zhang, Q. J., Wallace, L. E., Dolcetti, R., Rowe, M., Rickinson, A. B. & Masucci, M. G. 1993 HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. Science 260, 98-100.
24. De Campos-Lima, P. O., Levitsky, V., Imreh, M. P., Gavioli, R. & Masucci, M. G. 1997 Epitope-dependent selection of highly restricted or diverse T cell receptor repertoires in response to persistent infection by Epstein-Barr virus. J. Exp. Med. 186, 83-89.
25. Doxiadis, I. I. N., Smits, J. M. A., Schreuder, G. M. T., Persijn, G. G., Van Houwelingen, H. C., Van Rood, J. J. & Claas, F. H. 1996 Association between specific HLA combinations and probability of kidney allograft loss: the taboo concept. Lancet 348, 850-853.
26. Fiorillo, M. T., Maragno, M., Butler, R., Dupuis, M. L. & Sorrentino, R. 2000 CD8(+) T-cell autoreactivity to an HLA-B27-restricted self-epitope correlates with ankylosing spondylitis. J. Clin. Invest. 106, 47-53.
27. Fox, R. I., Chilton, T., Scott, S., Benton, L., Howell, F. V. & Vaughan, J. H. 1987 Potential role of Epstein-Barr virus in Sjogren's syndrome. Rheum. Dis. Clin. North Am. 13, 275-292.
28. Garboczi, D. N., Ghosh, P., Utz, U., Fan, Q. R., Biddison, W. E. & Wiley, D. C. 1996 Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 384, 134-141.
29. Garcia, K. C., Degano, M., Pease, L. R., Huang, M., Peterson, P. A., Teyton, L. & Wilson, A. 1998 Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen. Science 279, 1166-1172.
30. Gaston, J. S. H. & Waer, M. 1985 Virus-specific MHC-restricted T lymphocytes may initiate allograft rejection. Immunol. Today 6, 237-239.
31. Goldrath, A. W. & Bevan, M. J. 1999 Low-affinity ligands for the TCR drive proliferation of mature CD8+ T cells in lymphopenic hosts. Immunity 11, 183-190.
32. Gregory, C. D., Murray, R. J., Edwards, C. F. & Rickinson, A. B. 1988 Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T-cell surveillance. J. Exp. Med. 167, 1811-1824.
33. Hammarskjöld, M. L. & Simurda, M. C. 1992 Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity. J. Virol. 66, 6496-6501.
34. Hemmer, B., Vergelli, M., Pinilla, C., Houghten, R. & Martin, R. 1998 Probing degeneracy in T-cell recognition using peptide combinatorial libraries. Immunol. Today 19, 163-168.
35. Henle, G. & Henle, W. 1976 Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int. J. Cancer 17, 1-7.
36. Henle, G., Henle, W. & Horwitz, C. A. 1974 Antibodies to Epstein-Barr virus-associated nuclear antigen in infectious mononucleosis. J. Inf. Dis. 130, 231-239.
37. Henle, G., Lennette, E. T., Alspaugh, M. A. & Henle, W. 1979 Reumatoid factor as a cause of positive reactions in tests for Epstein-Barr virus-specific IgM antibodies. Clin. Exp. Immunol. 36, 415-422.
38. Henle, W., Henle, G., Andersson, J., Ernberg, I., Klein, G., Horwitz, C. A., Marklund, G., Rymo, L., Wellinder, C. & Straus, S. E. 1987 Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc. Natl Acad. Sci. USA 84, 570-574.
39. Heslop, H. E. & Rooney, C. M. 1997 Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol. Rev. 157, 217-222.
40. Hoffman, G. J., Lazarowitz, S. E. & Hayward, S. D. 1980 Monoclonal antibody against a 250 000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc. Natl Acad. Sci. USA. 77, 2979-2983.
41. Khanna, R., Burrows, S., Kurilla, M., Jacob, C. A., Misko, I., Sculley, T. B., Kieff, E. & Moss, D. J. 1992 Localisation of Epstein-Barr virus CTL epitopes in healthy immune donors using recombinant vaccinia: implications for vaccine development. J. Exp. Med. 176, 169-176.
42. Khanna, R., Burrows, S. R., Argaet, V. & Moss, D. J. 1994 Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line. Int. Immunol. 6, 639-645.
43. Khanna, R., Burrows, S. R. & Moss, D. J. 1995 Immune regulation in Epstein-Barr virus-associated diseases. Micnbiol. Rev. 59, 387-405.
44. Khanna, R., Burrows, S. R., Moss, D. J. & Silins, S. L. 1996 Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxicT-lymphocyte control of EBV-associated malignancies. J. Virol. 70, 5357-5362.
45. Khanna, R., Slade, R. W. Poulsen, L., Moss, D. J., Burrows, S. R., Nicholls, J. & Burrows, J. M. 1997a Evolutionary dynamics of genetic variation in Epstein-Barr virus isolates of diverse geographical origins: evidence for immune pressure-independent genetic drift. J. Virol. 71, 8340-8346.
46. Khanna, R., Slade, R. W., Poulsen, L., Moss, D. J., Burrows, S. R., Nicholls, J. & Burrows, J. M. 1997b Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells. J. Immunol. 159, 5782-5785.
47. + EBV-specific CTL. J. Immunol. 157, 3619-3625.
48. Khanna, R., Burrows, S. R., Nicholls, J. & Poulsen, L. M. 1998a Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxicT lymphocytes. Eur. J. Immunol. 28, 451-458.
49. Khanna, R., Busson, P., Burrows, S. R., Raffoux, C., Moss, D. J., Nicholls, J. M. & Cooper, L. 1998b Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells. Cancer Res. 58, 310-314.
50. Khanna, R. (and 12 others) 1999a Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with post-transplant lymphoproliferative disease. Proc. Natl Acad. Sci. USA 96, 10 391-10 396.
51. Khanna, R., Sherritt, M. & Burrows, S. R. 1999b EBV Structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350/gp85 CTL epitopes for vaccine design. J. Immunol. 162, 3063-3069.
52. + T cell expansion during regression of monoclonal EBV-associated posttransplant lymphoproliferative disorder. J. Immunol. 163, 500-506.
53. Laherty, C. D., Hu, H. M., Opipari, A. W., Wang, F. & Dixit, V. M. 1992 The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor κ B. J. Biol. Chem. 267, 24 157-24 160.
54. Lechler, R. I., Lombardi, G., Batchelor, J. R., Reinsmoen, N. & Bach, F. H. 1990 The molecular basis of alloreactivity. Immunol. Today 11, 83-88.
55. Lee, S. P., Morgan, J., Skinner, W. A., Thomas, S. R., Jones, S. R., Sutton, J., Khanna. R., Whittle, H. C. & Rickinson, A. B. 1995 Epstein-Barr virus isolates with the major cytotoxic T cell epitope are prevalent in a highly B35.01-positive African population. Eur. J. Immunol. 25, 102-110.
56. Lee, S. P., Constandinou, C. M., Thomas, W. A., Croom-Carter, D., Blake, N. W., Murray, P. G., Crocker, J. & Rickinson, A. B. 1998 Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on Epstein-Barr virus-specific cytotoxic T-cell recognition. Blood 92, 1020-1030.
57. Levitskaya, J., Coram, M., Levitsky, V., Imreh, S., Steigerwald-Mullen, P. M., Klein, G., Kurilla, M. G. & Masucci, M. G. 1995 Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375, 685-688.
58. Levitsky, V., De Campos-Lima, P. O., Frisan, T. & Masucci, M. G. 1998 The clonal composition of a peptide-specific oligoclonal CTL repertoire selected in response to persistent EBV infection is stable over time. J. Immunol. 161, 594-601.
59. Loh, J. E., Chang, C. H., Fodor, W. L., Flavell, R. A. 1992 Dissection of the interferon gamma-MHC class II signal transduction pathway reveals that type I and type II Interferon systems share common signalling component. EMBO J. 11, 1351-1363.
60. Maruya, E., Takemoto, S. & Terasaki, P. I. 1993 Clinical transplants (ed. P. I. Terasaki & J. M. Cecka), pp. 511-520. Los Angeles, CA: UCLA Tissue Typing Laboratory.
61. Mason, D. 1998 A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol. Today 19, 395-404.
62. Misko, I. S., Moss, D. J. & Pope, J. H. 1980 HLA antigenrelated restriction of T lymphocyte cytotoxicity to Epstein-Barr virus. Proc. Natl Acad. Sci. USA 77, 4247-4250.
63. Misko, I. S., Kane, R. G. & Pope, J. H. 1981 Restriction of foetal calf serum-induced cytotoxicity by human T-cells. Immunol. Lett. 3, 81-85.
64. Misko, I. S., Pope, J. H., Hutter, R., Soszynski, T. D. & Kane, R. G. 1984 HLA-DR-antigen-associated restriction of EBV-specific cytotoxic T-cell colonies. Int. J. Cancer. 33, 239-243.
65. Misko, I. S., Cross, S. M., Khanna, R., Elliott, S. L., Schmidt, C., Pye, S. J. & Silins, S. L. 1999 Crossreactive recognition of viral, self, and bacterial peptide ligands by human class I-restricted cytotoxic T lymphocyte clonotypes: implications for molecular mimicry in autoimmune disease. Proc. Natl Acad. Sci. USA 96, 2279-2284.
66. Miyashita, E. M., Yang, B., Babcock, G. J. & Thorley-Lawson, D. A. 1997 Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J. Virol. 71, 4882-4891.
67. Moghaddam, A., Rosenzweig, M., Lee-Parritz, D., Annis, B., Johnson, R. P. & Wang, F. 1997 An animal model for acute and persistent Epstein-Barr virus infection. Science 276, 2030-2033.
68. Morgan, A. J. 1992 Epstein-Barr virus vaccines. Vaccine 10, 563-570.
69. Moss, D. J., Rickinson, A. B. & Pope, J. H. 1978 Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes. Int. J. Cancer 22, 662-668.
70. Moss, D. J., Chan, S. H., Burrows, S. R., Chew, T. S., Kane, R. G., Staples, J. A. & Kunaratnam, N. 1983 Epstein-Barr virus T cell response in nasopharyngeal carcinoma patients. Int. J. Cancer 32, 301-305.
71. Moss, D. J., Bishop, C. J., Burrows, S. R. & Ryan, J. M. 1985 T lymphocytes in infectious mononucleosis. I. T cell death in vitro. Clin. Exp. Immunol. 60, 61-69.
72. Moss, D. J., Misko, I. S., Burrows, S. R., Burman, K. B., McCarthy, R. & Sculley, T. B. 1988 Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants. Nature 331, 719-721.
73. Nahill, S. R. & Welsh, R. M. 1993 High frequency of crossreactive cytotoxic T lymphocytes elicited during the virus-induced polyclonal cytotoxic T lymphocyte response. J. Exp. Med. 177, 317-327.
74. + T cells with a predominant V beta usage during the primary immune response to HIV. Nature 370, 463-467.
75. Pantaleo, G. (and 16 others) 1997 The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc. Natl Acad. Sci. USA 94, 254-258.
76. Pepperl, S., Benninger-Doring, G., Modrow, S., Wolf, H. & Jilg, W. 1998 Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes. J. Virol. 72, 8644-8649.
77. Pothen, S., Richert, J. R. & Pearson, G. R. 1991 Human T-cell recognition of Epstein-Barr virus-induced replication antigen complexes. Int. J. Cancer. 49, 656-660.
78. Pouteil-Noble, C., Ecochard, R., Landrivon, G., Donia-Maged, A., Tardy, J. C., Bosshard, S., Colon, S., Betuel, H., Aymard, M. & Touraine, J. L. 1993 Cytomegalovirus infection - an etiological factor for rejection? A prospective study in 242 renal transplant patients. Transplantation 55, 851-857.
79. Qualtiere, L. F., Chase, R. & Pearson, G. R. 1982 Purification and biologic characterization of a major Epstein-Barr virus-induced membrane glycoprotein. J. Immunol. 129, 814-818.
80. Rickinson, A. B. & Kieff, E. 1996 Epstein-Barr virus. In Fields' virology (ed. B. N. Fields, D. M. Knipe & P. M. Howley), pp. 2397-2446. Philadelphia, PA: Lippincott-Raven Publishers.
81. Rickinson, A. B. & Moss, D. J. 1997 Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. A. Rev. Immunol. 15, 405-431.
82. Rickinson, A. B., Moss, D. J. & Pope, J. H. 1979 Long-term T-cell mediated immunity to Epstein-Barr virus in man. II. Components necessary for regression in virus-infected leukocyte cultures. Int. J. Cancer 23, 610-617.
83. Rooney, C. M., Rowe, M., Wallace, L. E. & Rickinson, A. B. 1985 Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance, Nature 317, 629-631.
84. Rooney, C. M., Roskrow, M. A., Suzuki, N., Ng, C. Y., Brenner, M. K. & Heslop, H. 1998 Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Annls Oncol. 9, 129-132.
85. Roskrow, M. A., Suzuki, N., Gan, Y. J., Sixbey, J. W., Ng, C. Y., Kimbrough, S., Hudson, M., Brenner, M. K., Heslop, H. E. & Rooney, C. M. 1998 Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 91, 2925-2934.
86. Royston, I., Sullivan, J. L., Periman, P. O. & Perlin, E. 1975 Cell-mediated immunity to Epstein-Barr-virus-transformed lymphoblastoid cells in acute infectious mononucleosis. New Engl. J. Med. 293, 1159-1163.
87. Saal, J. G., Krimmel, M., Steidle, M., Gerneth, F., Wagner, S., Fritz, P., Koch, S., Zacher, J., Sell, S., Einsele, H. & Muller, C. A. 1999 Synovial Epstein-Barr virus infection increases the risk of rheumatoid arthritis in individuals with the shared HLA-DR4 epitope. Arthritis Rheum. 42, 1485-1496.
88. Schmidt, C. W. & Misko, I. S. 1995 The ecology and pathology of Epstein-Barr virus. Immunol. Cell Biol. 73, 489-504.
89. Sculley, T. B., Apolloni, A., Hurren, L., Moss, D. J. & Cooper, D. A. 1990 Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects J. Infect. Dis. 162, 643-648.
90. Sharrock, C. E. M., Kaminski, E. & Man, S. 1990 Limiting dilution analysis of human T cells: a useful clinical tool. Immunol. Today 11, 281-286.
91. Sherman, L. A. & Chattopadhyay, S. 1993 The molecular basis of allorecognition. A. Rev. Immunol. 11, 385-402.
92. Shimakage, M., Dezawa, T. & Chatani, M. 2000 Proper use of serum antibody titres against Epstein-Barr virus in nasopharyngeal carcinoma: IgA/virus capsid antigen for diagnosis and EBV-related nuclear antigen-2 for follow-up. Acta Otolaryngol. 120, 100-104.
93. Silins, S. L., Cross, S. M., Elliott, S. L., Pye, S. J., Burrows, S. R., Burrows, J. M., Moss, D. J., Argaet, V. P. & Misko, I. S. 1996 Development of Epstein-Barr virus-specific memory T cell receptor clonotypes in acute infectious mononucleosis. J. Exp. Med. 184, 1815-1824.
94. Silins, S. L., Cross, S. M., Elliott, S. L., Pye, S. J., Burrows, J. M., Moss, D. J. & Misko, I. S. 1997 Selection of a diverse TCR repertoire in response to an Epstein-Barr virus-encoded transactivator protein BZLF1 by CD8+ cytotoxic T lymphocytes during primary and persistent infection. Int. Immunol. 9, 1745-1755.
95. Silins, S. L., Cross, S. M., Krauer, K. G., Moss, D. J., Schmidt, C. W. & Misko, I. S. 1998 functional link for major TCR expansions in healthy adults caused by persistent Epstein-Barr virus infection. J. Clin. Invest. 102, 1551-1558.
96. Sixbey, J. W., Shirley, P., Chesney, P. J., Buntin, D. M. & Resnick, L. 1989 Detection of a second widespread strain of Epstein-Barr virus. Lancet ii, 761-765.
97. Smith, T. J., Terada, N., Robinson, C. C. & Gelfand, E. W. 1993 Acute infectious mononucleosis stimulates the selective expression/expansion of V beta 6.1-3 and V beta 7 T-cells. Blood 81, 1521-1526.
98. Sourdive, D. J., Murali-Krishna, K., Altman, J. D., Zajac, A. J., Whitmire, J. K., Pannetier, C., Kourilsky, P., Evavold, B., Sette, A. & Ahmed, R. 1998 Conserved T cell receptor repertoire in primary and memory CD8 T cell response to an acute viral infection. J. Exp. Med. 188, 71-82.
99. Steven, N. M., Annels, N. E., Kumar, A., Leese, A. M., Kurilla, M. G. & Rickinson, A. B. 1997 Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J. Exp. Med. 185, 1605-1617.
100. Strang, G. & Rickinson, A. B. 1987. Multiple HLA class I-dependent cytotoxicities constitute the 'non-HLA-restricted' response in infectious mononucleosis. Eur. J. Immunol. 17, 1007-1013.
101. Sutkowski, N., Palkama, T., Ciurli, C., Sekaly, R. P., Thorley-Lawson, D. A. & Huber, B. T. 1996 An Epstein-Barr virus-associated superantigen. J. Exp. Med. 184, 971-980.
102. Svedmyr, E. & Jondal, M. 1975 Cytotoxic effector cells specific for B cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis. Proc. Natl Acad. Sci. USA 72, 1622-1626.
103. + T cells specific for EBV in healthy virus carriers. J. Immunol. 162, 1827-1835.
104. Than, S., Kharbanda, M., Chitnis, V., Bakshi, S., Gregersen, P. K. & Pahwa, S. 1999 Clonal dominance patterns of CD8 T cells in relation to disease progression in HIV-infected children. J. Immunol. 162, 3680-3686.
105. + cytotoxic T cells: implications for vaccine design. Proc. Natl Acad. Sci. USA 92, 5845-5849.
106. Thomson, S. A. (and 12 others) 1996 Recombinant polypeptide vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J. Immunol. 157, 822-826.
107. Thorley-Lawson, D. A. & Babcock, G. J. 1999 A model for persistent infection with Epstein-Barr virus: the stealth virus of human B cells. Life Sci. 65, 1433-1453.
108. Thorley-Lawson, D. A. & Geilinger, K. 1980 Monoclonal antibodies against the major glycoprotein (gp 350/220) of Epstein-Barr virus neutralise infectivity. Proc. Natl Acad. Sci. USA 77, 5307-5311.
109. Tierney, R. J., Steven, N., Young, L. S. & Rickinson, A. B. 1994 Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J. Virol. 68, 7374-7385.
110. Torsteinsdottir, S., Brautbar, C., Klein, G., Klein, E. & Masucci, M. G. 1988 Differential expression of HLA antigens on human B-cell lines of normal and malignant origin: a consequence of immune surveillance or a phenotypic vestige of the progenitor cells? Int. J. Cancer 41, 913-919.
111. Wang, F., Gregory, C., Sample, C., Rowe, M., Liebowitz, D., Murray, R., Rickinson, A. & Kieff, E. 1990 Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J. Virol. 64, 2309-2318.
112. + virus-specific cytotoxic T cells which recognise Epstein-Barr virus lytic antigen BHRF1. Virology 219, 489-492.
113. + T cells following primary simian immunodeficiency virus infection. Eur. J. Immunol. 28, 1172-1180.
114. Xu, J., Ahmad, A., D'Addario, M., Knafo, L., Jones, J. F., Prasad, U., Dolcetti, R., Vaccher, E. & Menezes, J. 2000 Analysis and significance of anti-latent membrane protein-1 antibodies in the sera of patients with EBV-associated diseases. J. Immunol. 164, 2815-2822.
115. Yoshizaki, T., Miwa, H., Takeshita, H., Sato, H. & Furukawa, M. 2000 Elevation of antibody against Epstein-Barr virus genes BRLF1 and BZLF1 in nasopharyngeal carcinoma. J. Cancer Res. Clin. Oncol. 126, 69-73.